NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: AnaSpec, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Highly Sensitive SensoLyte® HDACs and HATs Assay Kits for Epigenetics Research - AnaSpec has developed a series of highly sensitive assay kits for the detection of the activities of enzymes involved in epigenetics such as HDAC (Histone Deacetylase), SIRT (Sirtuin) 1 & 2 or HAT (Histone Acetyltransferases)
Highly Sensitive SensoLyte® HDACs and HATs Assay Kits for Epigenetics Research

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/12/05 - AnaSpec has developed a series of highly sensitive assay kits for the detection of the activities of enzymes involved in epigenetics such as HDAC (Histone Deacetylase), SIRT (Sirtuin) 1 & 2 or HAT (Histone Acetyltransferases).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AnaSpec, EGT Group is pleased to offer a wide selection of highly sensitive HDAC (HDAC, SIRT1 & SIRT2) and HAT (CAF & p300) SensoLyte® assay kits. These assays are fluorimetric, some of which are FRET (fluorescence resonance energy transfer)-based.

Histones are the chief protein components of chromatin. They act as spools around which DNA winds. Covalent modification of histone proteins through acetylation and deacetylation affects chromatin structure and regulates gene expression. Histone hyperacetylation is well correlated with increased transcription, whereas hypoacetylation correlates with transcriptional repression. Histone deacetylases (HDACs), which catalyze the removal of acetyl groups from a ε-N-acetyl lysine amino acid on a histone, act as transcriptional repressors of genes. Histone deacetylases have been grouped into three classes. Class I (HDAC 1, 2, 3, 8) and Class II (HDAC4, 5, 6, 7, and 9) are zinc-containing hydrolase’s enzymes. The third class of deacetylases consists of the members of the sirtuin family of enzymes (Sirt 1 to 7). Inhibitors of HDAC classes I and II are being studied as a treatment for cancer and neurodegenerative diseases such as Huntington’s and Alzheimer’s diseases. The Sirtuin 1 (class III) enzyme represents a target for treatment of age-related diseases and type II diabetes.

Histone acetyltransferases (HATs) enzymes regulate the acetylation of histones and nonhistone proteins. The acetylation of the ε-amino groups of lysine residues present at histone tails correlates largely with transcriptional activation, but it is also involved in DNA replication, DNA repair and protein–protein interactions.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Highly Sensitive SensoLyte® HDACs and HATs Assay Kits for Epigenetics Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Cecilia Po - AnaSpec.com 
510-791-9560 cecilia[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering
DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
Veeva Widely Recognized for Leadership and Innovation in Support of Customers and Employees
Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management
Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)